Literature DB >> 27802092

Preservation of Reduced Numbers of Insulin-Positive Cells in Sulfonylurea-Unresponsive KCNJ11-Related Diabetes.

Siri Atma W Greeley1, Mark C Zielinski1, Ananta Poudel1, Honggang Ye1, Shivani Berry1, Jerome B Taxy2, David Carmody1, Donald F Steiner1, Louis H Philipson1, Jamie R Wood3, Manami Hara1.   

Abstract

Context: The most common genetic cause of permanent neonatal diabetes mellitus is activating mutations in KCNJ11, which can usually be treated using oral sulfonylureas (SUs) instead of insulin injections, although some mutations are SU unresponsive. In this work, we provide a report of the pancreatic islet endocrine cell composition and area in a patient with an SU-unresponsive KCNJ11 mutation (p.G334D), in comparison with age-matched controls. Case Description: Pancreatic autopsy tissue sections from a 2-year-old female child diagnosed with KCNJ11-related diabetes at 4 days of age and 13 age-matched controls were stained with insulin, glucagon, somatostatin, pancreatic polypeptide, and Ki67 antibodies to determine islet endocrine cell composition and area. β-cell ultrastructure was assessed by electron microscopic (EM) analysis. The patient's pancreas (sampling from head to tail) revealed insulin-positive cells in all regions. The pancreatic β-cell (insulin) area was significantly reduced compared with controls: 0.50% ± 0.04% versus 1.67% ± 0.20%, respectively (P < 0.00001). There were no significant differences in α-cell (glucagon) or δ-cell (somatostatin) area. EM analysis revealed secretory granules with a dense core typical of mature β-cells as well as granules with a lighter core characteristic of immature granules. Conclusions: Our results suggest that mechanisms exist that allow preservation of β-cells in the absence of insulin secretion. It remains to be determined to what extent this reduction in β-cells may be reversible.
Copyright © 2017 by the Endocrine Society

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27802092      PMCID: PMC5413092          DOI: 10.1210/jc.2016-2826

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  14 in total

1.  Age at the time of sulfonylurea initiation influences treatment outcomes in KCNJ11-related neonatal diabetes.

Authors:  Brian W Thurber; David Carmody; Elizabeth C Tadie; Ashley N Pastore; Jazzmyne T Dickens; Kristen E Wroblewski; Rochelle N Naylor; Louis H Philipson; Siri Atma W Greeley
Journal:  Diabetologia       Date:  2015-04-17       Impact factor: 10.122

2.  An ATP-binding mutation (G334D) in KCNJ11 is associated with a sulfonylurea-insensitive form of developmental delay, epilepsy, and neonatal diabetes.

Authors:  Ricard Masia; Joseph C Koster; Stefano Tumini; Francesco Chiarelli; Carlo Colombo; Colin G Nichols; Fabrizio Barbetti
Journal:  Diabetes       Date:  2007-02       Impact factor: 9.461

3.  Creation of the Web-based University of Chicago Monogenic Diabetes Registry: using technology to facilitate longitudinal study of rare subtypes of diabetes.

Authors:  Siri Atma W Greeley; Rochelle N Naylor; Lindsay S Cook; Susan E Tucker; Rebecca B Lipton; Louis H Philipson
Journal:  J Diabetes Sci Technol       Date:  2011-07-01

4.  Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.

Authors:  Ewan R Pearson; Isabelle Flechtner; Pål R Njølstad; Maciej T Malecki; Sarah E Flanagan; Brian Larkin; Frances M Ashcroft; Iwar Klimes; Ethel Codner; Violeta Iotova; Annabelle S Slingerland; Julian Shield; Jean-Jacques Robert; Jens J Holst; Penny M Clark; Sian Ellard; Oddmund Søvik; Michel Polak; Andrew T Hattersley
Journal:  N Engl J Med       Date:  2006-08-03       Impact factor: 91.245

5.  Diazoxide, a K(ATP) channel opener, prevents ischemia-reperfusion injury in rodent pancreatic islets.

Authors:  Yong Wang; Shusen Wang; Tricia Harvat; Katie Kinzer; Lisa Zhang; Feng Feng; Meirigeng Qi; Jose Oberholzer
Journal:  Cell Transplant       Date:  2013-09-10       Impact factor: 4.064

6.  Secondary consequences of beta cell inexcitability: identification and prevention in a murine model of K(ATP)-induced neonatal diabetes mellitus.

Authors:  Maria Sara Remedi; Harley T Kurata; Alexis Scott; F Thomas Wunderlich; Eva Rother; Andre Kleinridders; Ailing Tong; Jens C Brüning; Joseph C Koster; Colin G Nichols
Journal:  Cell Metab       Date:  2009-02       Impact factor: 27.287

7.  β-Cell Deficit in Obese Type 2 Diabetes, a Minor Role of β-Cell Dedifferentiation and Degranulation.

Authors:  Alexandra E Butler; Sangeeta Dhawan; Jonathan Hoang; Megan Cory; Kylie Zeng; Helga Fritsch; Juris J Meier; Robert A Rizza; Peter C Butler
Journal:  J Clin Endocrinol Metab       Date:  2015-12-23       Impact factor: 5.958

8.  Human pancreas endocrine cell populations and activating ABCC8 mutations.

Authors:  Kanetee Busiah; Virginie Verkarre; Hélène Cavé; Raphael Scharfmann; Michel Polak
Journal:  Horm Res Paediatr       Date:  2014-06-14       Impact factor: 2.852

9.  Reversible changes in pancreatic islet structure and function produced by elevated blood glucose.

Authors:  Melissa F Brereton; Michaela Iberl; Kenju Shimomura; Quan Zhang; Alice E Adriaenssens; Peter Proks; Ioannis I Spiliotis; William Dace; Katia K Mattis; Reshma Ramracheya; Fiona M Gribble; Frank Reimann; Anne Clark; Patrik Rorsman; Frances M Ashcroft
Journal:  Nat Commun       Date:  2014-08-22       Impact factor: 14.919

10.  Pancreas volumes in humans from birth to age one hundred taking into account sex, obesity, and presence of type-2 diabetes.

Authors:  Y Saisho; A E Butler; J J Meier; T Monchamp; M Allen-Auerbach; R A Rizza; P C Butler
Journal:  Clin Anat       Date:  2007-11       Impact factor: 2.414

View more
  6 in total

1.  Pancreatic Histopathology of Human Monogenic Diabetes Due to Causal Variants in KCNJ11, HNF1A, GATA6, and LMNA.

Authors:  May Sanyoura; Laura Jacobsen; David Carmody; Daniela Del Gaudio; Gorka Alkorta-Aranburu; Kelly Arndt; Ying Hu; Frances Kobiernicki; Irina Kusmartseva; Mark A Atkinson; Louis H Philipson; Desmond Schatz; Martha Campbell-Thompson; Siri Atma W Greeley
Journal:  J Clin Endocrinol Metab       Date:  2018-01-01       Impact factor: 5.958

Review 2.  Precision Medicine: Long-Term Treatment with Sulfonylureas in Patients with Neonatal Diabetes Due to KCNJ11 Mutations.

Authors:  Lisa R Letourneau; Siri Atma W Greeley
Journal:  Curr Diab Rep       Date:  2019-06-27       Impact factor: 4.810

Review 3.  Neonatal Diabetes and the KATP Channel: From Mutation to Therapy.

Authors:  Frances M Ashcroft; Michael C Puljung; Natascia Vedovato
Journal:  Trends Endocrinol Metab       Date:  2017-03-03       Impact factor: 12.015

4.  Successful transition from insulin to sulfonylurea, on second attempt, in a 24-year-old female with neonatal diabetes secondary to KCNJ11 gene mutation.

Authors:  Sulaiman Hajji; Khaled Aljenaee; Aoife Garrahy; Maria Byrne
Journal:  BMJ Case Rep       Date:  2021-04-09

5.  Genetic Spectrum of Neonatal Diabetes.

Authors:  M Kocova
Journal:  Balkan J Med Genet       Date:  2021-03-23       Impact factor: 0.519

6.  Severe Developmental Delay, Epilepsy and Neonatal Diabetes (DEND) Syndrome: A Case Report.

Authors:  Muhd Alwi Muhd Helmi; Suhaimi Hussain
Journal:  J ASEAN Fed Endocr Soc       Date:  2020-04-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.